1. Stocks that are in focus today: Cipla, ONGC, Wipro and more

Stocks that are in focus today: Cipla, ONGC, Wipro and more

Cipla stocks will be in focus today as the the Indian generic drugmaker on Friday informed BSE that its UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc for $550 million in an all cash transaction.

By: | Updated: September 4, 2015 10:16 AM
BSE Sensex

Cipla stocks will be in focus today as the the Indian generic drugmaker on Friday informed BSE that its UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc for 0 million in an all cash transaction.

The BSE Sensex and NSE Nifty opened on a weak note tracking mixed global cues. At 9.28 am, Sensex was down 227.36 points at 25,537.42. Similarly, Nifty was down 67.00 points at 7,756.00 during the same time.

Below are the stocks that are likely to be in focus today

Cipla: In a BSE filing today, the Indian generic drugmaker said that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc for $550 million in an all cash transaction.

Wipro: Country’s third-largest software services firm has been chosen as the official digital and IT partner for Chelsea Football Club.The financial details of the deal were not disclosed and the announcement was made after market hours on Thursday.

Lupin: Drug major Lupin has launched generic anti-depressant drug Duloxetine in 40 mg strength in the US market.

National Buildings Construction Corporation (NBCC): The state-owned NBCC has bagged contracts worth Rs 387 crore during last month.

ONGC: State-owned Oil and Natural Gas Corp (ONGC) has bought a 15 per cent stake in Russia’s second-largest oil field from Rosneft for about $1.35 billion.

Glenmark Pharma: Glenmark Pharmaceuticals has completed the clinical phase I studies for its novel monoclonal antibody ‘GBR 830’ for treating autoimmune diseases.

GVK: Green groups lost a fight to stop billionaire Gina Rinehart and India’s GVK from building a giant coal mine in Australia, as a court on Friday dismissed an appeal against the state of Queensland’s environmental approval for the project.

Ashok Leyland: Reserve Bank has allowed foreign investors to invest up to 40 per cent of the paid up capital in Ashok Leyland.

  1. No Comments.

Go to Top